Orthos secures funding for synthetic bone substitute

The material, which can be moulded by hand, has been specially designed to treat bone defects in the spine and, according to the company, could minimise the risk of infection associated with bone-implant surgery.

Orthos’ chief technology officer, Alan Rorke, said that its calcium-phosphate βGel would be more effective than existing granular versions currently on the market, as it could better mould into gaps found between defective bones.

‘The beta gel material takes the calcium-phosphate mineral and suspends it in a reverse-phase hydrogel,’ explained Rorke. ‘That means it has different mechanical and physical characteristics at different temperatures. So at room temperature it is liquid, but at body temperature it solidifies.’

The βGel can be delivered via an injection or used in putty form and only sets once it is inside the body. The existing bone can then use it as a scaffold while breaking down its minerals to help speed up the repair process.